1Ressmeyer AR, Mayo JC, Zelosko V et al. Antioxidant properties of the melatonin metabolite N1 - acetyl - 5 - methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep, 2003; 8 (4) : 205 - 213.
2Bruck R, Aeed H, Avni Y et al, Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rat, J Hepatol,2004; 40 (1): 86-93.
3Gilad E, Wong HR, Zingarelli Bet al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF- kappa B activation. FASEB J , 1998; 12 (9): 685-693.
4Scheer FA, Van Montfrans GA, Someren EJ et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension, 2004; 43 (2) : 192- 197.
5Nishiyama K, Yasue H, Moriyama Yet al. Acute effects of melatonin on cardiovascular autonomic regulation in healthymen. Am Heart J, 2001; 141 (5): E9.
6Sewwrynek E. Melalonin and the cardiovascular system. Neuro Endocrinol Lett, 2002; 23 (Suppl 1): 79- 83.
7Ekmekcioglu C, Thalhammer T, Humpeler S et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res, 2003 ; 35 (1) : 40 - 44.
8Arangino S, Cagnacci A, Angiolucci M et al. Effects of melatonin on vascular reactivity catecholamine levels, and blood pressure in healthy men. Am J Cardiol, 1999; 83 (9) : 1417-1419.
9Kimberly K, Monroe - Stephanie W. Watts. The vascular reactivity of melatonin. Gen Pharmac, 1998; 30 (1): 31-35.
10Nava M, Quiroz Y, Vaziri N et al. Melatonin reduces renal interstitical inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol - Renal Physiol,2003; 284 (3): F447-454.
